Tuberous sclerosis complex-associated kidney angiomyolipoma: From contemplation to action

Nephrology Dialysis Transplantation

Volumn 28, Issue 7, 2013, Pages 1680-1685

  Pirson, Yves ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

ADVANCED CANCER; ALBUMINURIA; ANGIOMYOLIPOMA; CLINICAL FEATURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GONADAL DISEASE; HISTORY OF MEDICINE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INTERSTITIAL PNEUMONIA; KIDNEY ANGIOMYOLIPOMA; LEG EDEMA; LYMPHANGIOLEIOMYOMATOSIS; MENSTRUATION DISORDER; MOUTH ULCER; NEPHROTIC SYNDROME; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SIDE EFFECT; SPERMATOZOON COUNT; SPERMATOZOON MOTILITY; STOMATITIS; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS; TUMOR VOLUME; WOUND HEALING IMPAIRMENT;

ANGIOMYOLIPOMA; ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY NEOPLASMS; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS;

EID: 84884510716     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft009     Document Type: Review

References (38)

1. Bissler JJ, McCormack FX, Young LR et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-151
2. Davies DM, de Vries PJ, Johnson SR et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 2011; 17: 4071-4081
3. Dabora SL, Franz DN, Ashwal S et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS One 2011; 6: e23379 Epub 2011 Sep 6
4. Cabrera López C, Martí T, Catalá V et al. Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis. Nefrologia 2011; 31: 292-298
5. Krueger DA, Care MM, Holland K et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med; 2010; 363: 1801-1811
6. McCormack FX, Inoue Y, Moss J et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364: 1595-1606
7. Wataya-Kaneda M, Tanaka M, Nakamura A et al. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. Br J Dermatol 2011; 165: 912-916
8. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372: 657-668
9. Budde K, Gaedeke J. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition. Am J Kidney Dis 2012; 59: 276-283
10. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998; 13: 624-628
11. Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci 1991; 615: 125-127
12. Seibert D, Hong CH, Takeuchi F et al. Recognition of tuberous sclerosis in adult women: delayed presentation with life-threatening consequences. Ann Intern Med 2011; 154: 806-813
13. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006; 355: 1345-1356
14. Yamakado K, Tanaka N, Nakagawa T et al. Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology 2002; 225: 78-82
15. Cox J, Kingswood J, Mbundi J et al. The natural history of renal angiomyolipomata (AMLs) in tuberous sclerosis complex (TSC). Abstract 2012-SAP029 ERA-EDTA Congress
16. Balligand JL, Pirson Y, Squifflet JP et al. Outcome of patients with tuberous sclerosis after renal transplantation. Transplantation 1990; 49: 515-518
17. van Slegtenhorst M, de Hoogt R, Hermans C et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277: 805-808
18. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993; 75: 1305-1315
19. Kenerson HL, Aicher LD, True LD et al. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002; 62: 5645-5650
20. Lee L, Sudentas P, Donohue B et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 2005; 42: 213-227
21. Franz DN, Leonard J, Tudor C et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59: 490-498
22. Wienecke R, Fackler I, Linsenmaier U et al. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 2006; 48: e27-e29
23. Zonnenberg B, Budde K, Kingswood C et al. Angiomyolipoma response to everolimus treatement in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis : results from exist-2. Abstract 2012-SUO017 ERA-EDTA Congress
24. Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus for calcineurin inhibitors in organ transplantation: contra. Kidney Int 2010; 78: 1068-1074
25. Tiong HY, Flechner SM, Zhou L et al. A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients. Transplantation 2009; 87: 296-302
26. Huyghe E, Zairi A, Nohra J et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int 2007; 20: 305-311
27. Zuber J, Anglicheau D, Elie C et al. Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant 2008; 8: 1471-1479
28. Braun M, Young J, Reiner CS et al. Ovarian toxicity from sirolimus. N Engl J Med 2012; 366: 1062-1064
29. Budde K, Becker T, Arns W et al. Everolimus-based, calcineurininhibitor- free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377: 837-847
30. Serra AL, Poster D, Kistler AD et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 820-829
31. Stallone G, Infante B, Pontrelli P et al. Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplant 2011; 91: 997-1004
32. Cinà DP, Onay T, Paltoo A et al. Inhibition of MTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol 2012; 23: 412-420
33. Oroszlan M, Bieri M, Ligeti N et al. Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiontensin II-dependent pathway. Transplant Immunol 2010; 23: 125-132
34. Pinheiro HS, Amaro TA, Braga AM et al. Post-rapamycin proteinuria: incidence, evolution and therapeutic handling at a single center. Transplant Proc 2006; 38: 3476-3478
35. Wadei HM, Zaky ZS, Keaveny AP et al. Proteinuria following sirolimus conversion is associated with deterioration of kidney function in liver transplant recipients. Transplant 2012; 93: 1006-1012
36. Halpenny D, Snow A, McNeill G et al. The radiological diagnosis and treatment of renal angiomyolipoma-current status. Clin Radiol 2010; 65: 99-108
37. Castle SM, Gorbatiy V, Ekwenna O et al. Radiofrequency ablation (RFA) therapy for renal angiomyolipoma (AML): an alternative to angio-embolization and nephron-sparing surgery. BJU Int 2012; 109: 384-387
38. Bissler JJ, Coombs EJ, Dixon BP et al. The effect of everolimus dose and schedule on renal angiomyolipoma in patients with tuberous sclerosis complex. Abstract 2011-THP0817 ASN Congress